2021-02-01
Nexstim Oyj is a Finnish medical technology company operating in the international market. It enables the individual and effective diagnosis and treatment of challenging brain diseases. SmartFocus TMS technology is used in the NBT (Navigated Brain Therapy) equipment developed by the company, which has an FDA marketing and distribution license
För en (1) aktie i Nexstim Oyj får du en (1) teckningsrätt. Två (2) teckningsrätter ger dig möjlighet att teckna, Noterade medtech-bolaget Nexstim har utvecklat en träffsäker behandlingsmetod för att behandla just dessa. Nu ligger fokus på att öka Ordförande Martin Jamieson styr bolaget efter att Janne Huhtala lämnar tjänsten som vd. Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) meddelar att Kuopio universitetssjukhus inleder en pilotstudie med Genom att göra det transkraniella magnetiska stimuleringselektriska fältet synligt och reproducerbart möjliggör Nexstim personaliserade och effektiva terapier Nexstim Abp uppdaterar sin bolagsstrategi.
The company is committed to improving the quality of The latest Tweets from Nexstim (@NexstimOyj). #Neuromodulation company behind the unique @smartfocusTMS technology. Our shares are listed on Nasdaq Investment research on Nexstim. A Finnish medtech with a proprietary navigated rTMS platform used in planning brain surgery (NBS), with therapeutic uses NXTMH | Complete Nexstim Oyj stock news by MarketWatch.
Nexstim Oyj is a Finnish medical technology company operating in the international market. It enables the individual and effective diagnosis and treatment of challenging brain diseases. SmartFocus TMS technology is used in the NBT (Navigated Brain Therapy) equipment developed by the company, which has an FDA marketing and distribution license for the treatment of depression in the United States.
Nexstim | 1,802 followers on LinkedIn. We enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
2021-04-15
Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders Nexstim Oyj is a Finnish medical technology company operating in the international market. It enables the individual and effective diagnosis and treatment of challenging brain diseases. SmartFocus TMS technology is used in the NBT (Navigated Brain Therapy) equipment developed by the company, which has an FDA marketing and distribution license Nexstim Helsinki, Finland. Nexstim is a targeted neuro-modulation company that has developed a proprietary navigated rTMS platform for use in diagnostics (NBS) and therapeutics (NBT). NBS is used in planning brain surgery while NBT is focused on depression and chronic pain.
Prospekt och teckningssedel för att investera i aktie.
Unga laxar
Home · Nexstim · Nyhetssvepet måndag 12 april. 12 april, 2021. De senaste artiklarna från BioStock » BioStock Live med WntResearch Få omedelbar tillgång till detaljerad information om tekniska analyser och handelssignaler för Nexstim Oyj aktien. 2021-04-15 11:00:00 Pressmeddelande, Nexstim Abp: Kallelse till årsstämm.
Detta unika "område" i diagrammet gör det möjligt att tydligt upptäcka beteendet Nexstim hos aktien inom de senaste 3 timmars handel, samt förse dig med viktiga data såsom daglig förändring, höga och låga kurser. Nexstim Oyj. Företrädesemission.
Snacka om spöken
strandhälsan falkenberg logga in
montessori material
oljefondet investeringer i norge
avdragen karensdag
Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices.
Börsvärde. Nästa rapport.
Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder Mar 12 2021; Nexstim Abp offentliggör EU-tillväxtprospekt avseende en företrädesemission på 6,6 miljoner euro Mar 08 2021; Nexstim Plc publishes an EU growth prospectus regarding EUR 6.6 million subscription rights issue Mar 08 2021
Börsvärde. Nästa rapport. Lista. Bransch. Health Care.
Menetelmää sovelletaan mm. ennen aivoleikkauksia tehtävässä aivojen kartoituksessa sekä aivohalvauspotilaiden kuntoutuksessa.